Influence of intravenous acetylsalicylic acid and sodium salicylate on human renal function and lithium clearance.
The influence of intravenous acetylsalicylic acid (ASA; D,L-lysine-mono-acetylsalicylate), equimolar doses of sodium salicylate (SA) and placebo (P) on renal function has been studied in 6 healthy female volunteers, in 150 mmol sodium balance, and in lithium (Li) steady state with a plasma Li between 0.6 and 0.8 mmol/l. Following a bolus injection of 0.5 g ASA, 0.444 g SA or P (50 ml saline) given over 10 min and a subsequent continuous infusion of 1.5 g ASA, 1.332 SA or P (150 ml saline) over 170 min, urine was collected for 3 h as well as 6 plasma samples at 30-min intervals. Plasma ASA levels were between 13.8 and 22.1 micrograms/ml and for SA they were 20.8 to 82.6 microgram/ml during ASA infusion, and between 22.5 and 108.9 microgram/ml for SA during SA infusion. Neither ASA nor SA caused a significant change in urine volume, in the renal clearances of Na, K, free water, osmolality, creatinine, inulin and p-aminohippurate (PAH) or in plasma Li level. Renal Li clearance was slightly reduced by SA, from 37.8 to 29.4 ml/min (p less than 0.05). Since renal prostaglandin (PG) synthesis (urinary PGE2 excretion) was 60.6% suppressed by ASA and was not affected by SA, the decrease in Li clearance cannot be related to inhibition of cyclooxygenase in the kidney.
D000328:Adult; D001241:Aspirin / Q000008:administration & dosage / Q000378:metabolism*; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000378:metabolism; D003692:Delayed-Action Preparations; D015232:Dinoprostone; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D007275:Injections, Intravenous; D007444:Inulin / Q000378:metabolism; D007668:Kidney / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology; D008094:Lithium / Q000008:administration & dosage / Q000378:metabolism*; D008875:Middle Aged; D011458:Prostaglandins E / Q000378:metabolism; D011897:Random Allocation; D012980:Sodium Salicylate / Q000008:administration & dosage / Q000378:metabolism*; D010130:p-Aminohippuric Acid / Q000378:metabolism
D003692:Delayed-Action Preparations; D011458:Prostaglandins E; D007444:Inulin; D008094:Lithium; D003404:Creatinine; D015232:Dinoprostone; D001241:Aspirin; D012980:Sodium Salicylate; D010130:p-Aminohippuric Acid